Radiotherapy in the Elderly Cancer Patients

tibbi onkoloji ozel 13-4 kapak

Rıza ÇETİNGÖZa

aDokuz Eylül Üniversitesi Tıp Fakültesi, Radyasyon Onkolojisi ABD, İzmir, TÜRKİYE

ABSTRACT
Radiotherapy is one of the most important treatment modalities in cancer treatment and is used with curative and palliative aims. Standard treatments are not well established in the elderly because of the lack of randomized trials. Higher radiotherapy doses can be delivered with modern radiotherapy techniques with less side effects. Radiotherapy can be applied with success in the elderly and increases the local control, overall survival and quality of life. Therefore, having the radiation oncologist opinion before the final treatment decision is very important. In this review the role of radiotherapy in the elderly will be discussed in the light of current literature.
Keywords: Radiotherapy; elderly; cancer

Referanslar

  1. Thakkar JP, Mccarthy BJ, Villano Jl. Age-specific cancer incidence rates increase through the oldest age groups. Am J Med sci. 2014;348(1):65-70. [Crossref]  [PubMed]  [PMC]
  2. Smith BD, smith Gl, Hurria A, Hortobagyi GN, Buchholz TA. Future of cancer incidence in the united states: burdens upon an aging, changing nation. J clin Oncol 2009;10;27 (17): 2758-65. [Crossref]  [PubMed]
  3. Delva F, Marien E, Fonck M, Rainfray M, Demeaux Jl, Moreaud P, et al. Factors influencing general practitioners in the referral of elderly cancer patients. BMc cancer. 201;11:5. [Crossref]  [PubMed]  [PMC]
  4. Chaïbi P, Magné N, Breton s, chebib A, Watson s, Duron JJ, et al. Influence of geriatric consultation with comprehensive geriatric assessment on final therapeutic decision in elderly cancer patients. crit Rev Oncol Hematol. 2011; 79(3):302-7. [Crossref]  [PubMed]
  5. Handforth c, clegg A, Young c, simpkins s, seymour MT, selby PJ, et al. The prevalence and outcomes of frailty in older cancer patients: a systematic review Ann Oncol. 2015;26(6):1091-101. [Crossref]  [PubMed]
  6. National comprehensive cancer Network clinical Practice Guidelines in Oncology: Nonsmall cell lung cancer. Published 2018 [Link]
  7. Chang JY, senan s, Paul MA, Mehran RJ, louie AV, Balter P, et al: stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. lancet Oncol. 2015; 16: 630-7. [Crossref]  [PubMed]
  8. Nanda RH, liu Y, Gillespie TW, Mikell Jl, Ramalingam ss, Fernandez FG. et al. stereotactic body radiation therapy versus no treatment for early stage non-small cell lung cancer in medically inoperable elderly patients: a National cancer Data Base analysis. cancer. 2015; 121:4222-30. [Crossref]  [PubMed]
  9. Raz DJ, Zell JA, Ou sH, Gandara DR, Antonculver H, Jablons DM. et al. Natural history of stage I non‐small cell lung cancer: implications for early detection. chest. 2007;132:193‐9. [Crossref]  [PubMed]
  10. Pallis AG, Gridelli c, van Meerbeck JP, Greillier l, Wedding u, lacombe D, et al. EORTc Elderly Task Force and lung cancer Group and International society for Geriatric Oncology (sIOG) expert's opinion for the treatment of non-small cell lung cancer in an elderly population. Ann Oncol. 2010:21(4):692-706. [Crossref]  [PubMed]
  11. Rossi A, Maione P, colantuoni G, Guerriero c, Ferrara c, Del Gaizo F, et al. Treatment of small cell lung cancer in the elderly. The Oncologist. 2005;10:399-411. [Crossref]  [PubMed]
  12. Schild sE, Zhao l, Wampfler JA, Daniels TB, sio T, Ross HJ et al. small cell lung cancer in very elderly (≥ 80 Years) patients. clin lung cancer. 2019;20(4):313-21. [Crossref]  [PubMed]
  13. Hughes Ks1, schnaper lA, Bellon JR, cirrincione cT, Berry DA, Mccormick B, et al. lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of cAlGB 9343. J clin Oncol. 2013;31(19): 2382-7. [Crossref]  [PubMed]  [PMC]
  14. Martelli G, Boracchi P, Guzzetti E, Marano G, lozza l, Agresti R, et al. Omission of radiotherapy in elderly patients with early breast cancer: 15-Year results of a prospective nonrandomised trial. Eur J cancer. 2015; 51 (11): 1358-64. [Crossref]  [PubMed]
  15. Veronesi u, Marubini E, Mariani l, Galimberti V, luini A, Veronesi P, et al. Radiotherapy after breast-conserving surgery in small breast carcinoma: long-term results of a randomized trial. Ann Oncol. 2001;12(7): 997-1003. [Crossref]  [PubMed]
  16. Tinterri c, Gatzemeier W, costa A, Gentilini M. A, Zanini V, Regolo l. Breast-conservative surgery with and without radiotherapy in patients aged 55-75 years with early-stage breast cancer: A prospective, randomized, multicenter trial analysis after 108 months of median follow-up Ann surg Oncol. 2014; 21(2): 408-15. [Crossref]  [PubMed]
  17. Van de Water W, Bastiaannet E, scholten AN, Kiderlen M, de craen AJ, Westendorp RG, et al. Breast-conserving surgery with or without radiotherapy in older breast patients with early stage breast cancer: a systematic review and meta-analysis. Ann surg Oncol. 2014;21(3): 786-94 [Crossref]  [PubMed]
  18. Williams lJ, Kunkler IH, King cc, Jack W, van der Pol M. A randomised controlled trial of post-operative radiotherapy following breastconserving surgery in a minimum-risk population. Quality of life at 5 years in the PRIME trial. Health Technol Assess. 2011;15(12). [Crossref]
  19. sTART Trialists' Group, Bentzen sM, Agrawal RK, Aird EG, Barrett JM, Barrett-lee PJ, Bliss JM, et al. The uK standardisation of Breast Radiotherapy (sTART) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. lancet Oncol. 2008;9(4):331-41. [Crossref]  [PubMed]
  20. sTART Trialists' Group, Bentzen sM, Agrawal RK, Aird EG, Barrett JM, Barrett-lee PJ, Bentzen sM, et al. The uK standardisation of Breast Radiotherapy (sTART) Trial B of radiotherapyhypofractionation for treatment of early breast cancer: a randomised trial lancet. 2008 29;371(9618):1098-107. [Crossref]  [PubMed]
  21. Whelan TJ, Pignol JP, levine MN, Julian JA, MacKenzie R, Parpia set al. long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med. 2010 11;362(6):513-20. [Crossref]  [PubMed]
  22. Olivotto IA, Whelan TJ, Parpia s, Kim DH, Berrang T, Truong PT et al. J clin Oncol. Interim cosmetic and toxicity results from RAPID: a randomized trial of accelerated partial breast irradiation using three-dimensional conformal external beam radiation Therapy. 2013 10;31(32):4038-45. [Crossref]  [PubMed]
  23. Livi l, Meattini I, Marrazzo l, simontacchi G, Pallotta s, saieva c, et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5- year survival analysis of a phase 3 randomised controlled trial. Eur J cancer. 2015;51(4):451-63. [Crossref]  [PubMed]
  24. Vaidya Js, Wenz F, Bulsara M, Tobias Js, Joseph DJ, Keshtgar M, et al. TARGIT trialists' group. Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGITA randomised trial. lancet. 2014;383(9917):603-613. [Crossref]  [PubMed]
  25. Veronesi u, Orecchia R, Maisonneuve P, Viale G, Rotmensz N, sangalli c, et al. Intraoperative radiotherapy versus external radiotherapy for early breast cancer (ElIOT): a randomised controlled equivalence trial. lancet Oncol. 2013;14(13):1269-77. [Crossref]  [PubMed]
  26. Showalter sl, Petroni G, Trifiletti DM, libby B, schroen AT, Brenin DR, et al A novel form of breast intraoperative radiation therapy with cT-guided high-dose-rate brachytherapy: Results of a prospective phase 1 clinical trial. Int J Radiat Oncol Biol Phys. 2016;96(1):46-54. [Crossref]  [PubMed]
  27. Jones cu, Hunt D, McGowan DG, Amin MB, chetner MP, Bruner DW et al. Radiotherapy and short-term deprivation for localized prostate cancer. N Engl J Med. 2011; 365:107-18. [Crossref]  [PubMed]
  28. Bolla M, de Reijke TM, Van Tienhoven GV, Van den Bergh Ac, Oddens J, Poortmans PM et al. Duration of androgen suppression in the treatment of prostate cancer. N Engl J Med. 2009;360:2516-27. [Crossref]  [PubMed]
  29. Arcangeli G, Fowler J, Gomellini s, Arcangeli s, saracino B, Petrongari MG et al. Acute and late toxicity in a randomized trial of conventional versus hypofractionated three-dimensional conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2011;79:1013-21. [Crossref]  [PubMed]
  30. Katz A. stereotactic Body Radiotherapy for low-Risk Prostate cancer: A ten year analysis cureus. 2017;9:9:e1668. [Crossref]  [PubMed]  [PMC]
  31. Mbeutcha A, chauveinc l, Bondiau PY, chand ME, Durand M, chevallier D, et al. salvage prostate re-irradiation using high-dose-rate brachytherapy or focal stereotactic body radiotherapy for local recurrence after definitive radiation therapy. Radiat Oncol. 2017;12:49:2- 10 [Crossref]  [PubMed]  [PMC]
  32. Fuller DB, Wurzer J, shirazi R, Bridge ss, law J, Mardirossian G. High-dose-rate stereotactic body radiation therapy for postradiation therapy locally recurrent prostatic carcinoma: Preliminary prostate-specific antigen response, disease-free survival, and toxicity assessment. Pract Radiat Oncol. 2015;5:e615-e23. [Crossref]  [PubMed]
  33. Paydar I, Pepin A, cyr RA, King J, Yung TM, Bullock EG et al. Intensity-Modulated Radiation Therapy with stereotactic Body Radiation Therapy Boost for unfavorable Prostate cancer: A Report on 3-Year Toxicity. Front Oncol. 2017;7:5:1-9. [Crossref]  [PubMed]  [PMC]
  34. Boyle HJ, Alibhai s, Decoster l, Efstathiou E, Fizazi K, Mottet N, et al. updated recommendations of the International society of Geriatric Oncology on prostate cancer management in older patients. Eur J cancer. 2019;116:116-36. [Crossref]  [PubMed]
  35. scholten AN, van Putten Wl, Beerman H, smit VT, Koper Pc, lybeert Ml, et al. PORTEc study Group. Postoperative radiotherapy for stage 1 endometrial carcinoma: long-term outcome of the randomized PORTEc trial with central pathology review. Int J Radiat Oncol Biol Phys. 2005;63(3):834- 8. [Crossref]  [PubMed]
  36. Nout RA, Putter H, Jürgenliemk-schulz IM, Jobsen JJ, lutgens lc, van der steen-Banasik EM, et al. Five-year quality of life of endometrial cancer patients treated in the randomised Post Operative Radiation Therapy in Endometrial cancer (PORTEc-2) trial and comparison with norm data. Eur J cancer. 2012;48(11):1638-48. [Crossref]  [PubMed]
  37. Kong A, Johnson N, Kitchener Hc, lawrie TA. Adjuvant radiotherapy for stage I endometrial cancer: an updated cochrane systematic review and meta-analysis. J Natl cancer Inst. 2012;104(21):1625-34. [Crossref]  [PubMed]
  38. strohl MP, Raigani s, Ammori JB, Hardacre JM, Kim JA. et al. surgery for localized Pancreatic cancer: The Trend Is Not Improving.Pancreas. 2016;45(5):687-93. [Crossref]  [PubMed]
  39. Ciabatti s, cammelli s, Frakulli R, Arcelli A, Macchia G, Deodato F, et al. Radiotherapy of pancreatic cancer in older patients: A systematic review. J Ger Oncol: 2019;10:534-539 [Crossref]  [PubMed]
  40. Vlacich G, samson PP, Perkins sM, Roach Mc, Parikh PJ, Bradley JD, et al. Treatment utilization and outcomes in elderly patients with locally advanced esophageal carcinoma: a review of the National cancer Database. cancer Med. 2017;6(12):2886-96. [Crossref]  [PubMed]  [PMC]
  41. song T, Fang M, Wu s. concurrent chemoradiation therapy tailored to the older adults with esophageal cancer: state of the art and the future. clin Interv Aging. 2018;13:2275-87. [Crossref]  [PubMed]  [PMC]
  42. Bai XH, Dang J, chen ZQ, He Z, li G. comparison between intensity-modulated radiotherapy and three-dimensional conformal radiotherapy for their effectiveness in esophageal cancer treatment: A retrospective single institution study. J Oncol. 2020: 20:6582341. [Crossref]  [PubMed]  [PMC]
  43. sauer R, liersch T, Merkel s, Fietkau R, Hohenberger W, Hess c, et al. Operative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German cAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J clin Oncol. 2012;30(16):1926-33. [Crossref]  [PubMed]
  44. De Felice F, crocetti D, Maiuri V, Parisi M, Marampon F, Izzo l, et al. locally Advanced Rectal cancer: Treatment Approach in Elderly Patients. curr Treat Options Oncol. 2020;21(1):1. [Crossref]  [PubMed]
  45. Kobiela J, spychalski P, Marvaso G, ciardo D, Dell'Acqua V, Kraja F, et al. Ablative stereotactic radiotherapy for oligometastatic colorectal cancer: systematic review. crit Rev Oncol Hematol. 2018;129:91-101. [Crossref]  [PubMed]
  46. Fisher Jl, schwartzbaum JA, Wrensch M, Wiemels Jl. Epidemiology of brain tumors. Neurol clin. 2007;25(4):867-90. [Crossref]  [PubMed]
  47. scott J, Tsai Y-Y, chinnaiyan P, Yu H-HM, Effectiveness of radiotherapy for elderly patients with glioblastoma. Int J Radiat Oncol Biol Phys. 2011;81:206-10. [Crossref]  [PubMed]
  48. Iwamoto FM, cooper AR, Reiner As, Nayak l, Abrey lE. Glioblastoma in the elderly: the Memorial sloan-Kettering cancer center Experience (1997-2007).cancer. 2009;115(16): 3758-66. [Crossref]  [PubMed]  [PMC]
  49. Okada M, Miyake K, Tamiya T. Glioblastoma Treatment in the Elderly. Neurol Med chir (Tokyo). 2017;57(12):667-76. [Crossref]  [PubMed]  [PMC]
  50. Asmaa A, Dixit s, Rowland-Hill c, Achawal s, Rajaraman c, O'Reilly G, et al. Management of elderly patients with glioblastoma-multiforme-a systematic review. Br J Radiol 2018; 91: 20170271. [Crossref]  [PubMed]  [PMC]
  51. Higuchi Y, Yamamoto M, serizawa T, sato Y, shuto T, Akabane A, et al. stereotactic radiosurgery in elderly patients with brain metastases: comparison with non-elderly patients using database of a multi-institutional prospective observational study (JlGK0901-Elderly). J Neurooncol. 2019;144(2):393-402. [Crossref]  [PubMed]